Viridian Therapeutics, Inc. (VRDN) Financial Statements
Viridian Therapeutics, Inc. (VRDN) reported trailing twelve-month revenue of $71.1M (up 858.2% year on year) and net income of -$387.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$335.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VRDNViridian Therapeutics, Inc.Follow VRDN — free
—
Price chart with a free account
- Market cap
- 2.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 | |
| Gross profit | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | |
| Research & development | 0.00 | 0.00 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | 0.06 | 0.10 | 0.16 | 0.24 | 0.34 | 0.32 | |
| Operating income | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.04 | -0.11 | -0.08 | -0.13 | -0.25 | -0.30 | -0.36 | -0.41 | |
| Pre-tax income | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.04 | -0.11 | -0.08 | -0.13 | -0.24 | -0.27 | -0.34 | -0.39 | |
| Income tax | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | 0.00 | — | |
| Net income | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.04 | -0.11 | -0.08 | -0.13 | -0.24 | -0.27 | -0.34 | -0.39 | |
| Diluted EPS ($) | -3.50 | -21.02 | -28.21 | -1.38 | -1.10 | -20.04 | -31.13 | -6.66 | -4.05 | -5.31 | — | — | — | |
| Diluted shares (bn) | — | — | — | — | — | — | — | 0.012 | 0.032 | 0.045 | — | — | — |
USD billions · SEC XBRL
Viridian Therapeutics, Inc. — questions
- What is Viridian Therapeutics, Inc.'s revenue?
- $71.1M over the twelve months to 2026-06-30, up 858.2% year on year, from its 10-Q and 10-K filings.
- What is Viridian Therapeutics, Inc.'s net income?
- -$387.0M over the twelve months to 2026-06-30.
- What is Viridian Therapeutics, Inc.'s free cash flow?
- -$335.0M over the twelve months to 2026-06-30.
Every figure on this page comes from Viridian Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.